Kyverna Therapeutics, INC Form 4 insider transactions

Kyverna Therapeutics CEO Warner Weston Biddle reports acquisition of stock options on September 16, 2024.

Director Christi Shaw acquired stock options for 66,592 shares of Kyverna Therapeutics common stock on September 16, 2024.

Karen Walker, Chief Technology Officer of Kyverna Therapeutics, exercised stock options on June 6, 2024.

Ryan Alexander Jones, CFO of Kyverna Therapeutics, exercised stock options to acquire shares of common stock at a price of $0.73 on May 28, 2024.